RNAZ
Transcode Therapeutics, Inc.Company Information
- Company Name
- Transcode Therapeutics, Inc.
- CIK
- CIK0001829635
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- RNAZ: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RNAZ
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-09-28
- Last sale
- —
- Shares purchased (TTM)
- 178,350
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 35,039
- Shares outstanding
- 957,191
- Ownership
- 3.66%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -37.20%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Warrants | -0 | 1 | 0 | 0 | 0 | 0 | 1 | - | - | - | - | - | ||||||
| Series D Warrants | - | - | - | - | - | 0 | 0 | - | - | - | - | - | ||||||
| Series A Preferred Stock | -0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Series B Preferred Stock | -0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Series C Preferred Stock | -1 | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 8 | 13 | 18 | 3 | 7 | 12 | 6 | 2 | 3 | 5 | 3 | 7 | ||||||
| Grants Receivable Current | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Other Receivables Net Current | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | ||||||
| Assets Current | 11 | 17 | 22 | 5 | 8 | 13 | 7 | 4 | 4 | 7 | 4 | 9 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Security Deposit | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Goodwill | 26 | 26 | 26 | - | - | - | - | - | - | - | - | - | ||||||
| Intangible Assets Net Excluding Goodwill | 114 | 114 | 114 | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Costs | - | 0 | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Assets | 151 | 157 | 162 | 5 | 8 | 13 | 7 | 4 | 5 | 7 | 5 | 10 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 5 | 5 | 3 | 3 | 2 | 3 | 3 | 2 | 3 | 2 | 3 | 5 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Notes Payable Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 5 | 5 | 3 | 3 | 2 | 3 | 3 | 2 | 4 | 3 | 3 | 6 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 6 | 6 | 6 | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Noncurrent | 7 | 7 | 7 | 1 | 1 | 0 | 7 | - | - | - | 0 | - | ||||||
| Liabilities | 13 | 13 | 11 | 4 | 2 | 3 | 9 | 2 | 4 | 3 | 4 | 6 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 95 | 117 | 108 | 86 | 86 | 86 | 61 | 59 | 56 | 54 | 48 | 47 | ||||||
| Retained Earnings Accumulated Deficit | -122 | -116 | -98 | -84 | -80 | -75 | -63 | -57 | -55 | -50 | -46 | -42 | ||||||
| Number Of Reverse Splits Effected | - | - | - | - | - | - | 0 | - | - | - | - | - | ||||||
| Stockholders Equity | -28 | 1 | 10 | 1 | 6 | 10 | -2 | 2 | 1 | 5 | 2 | 4 | ||||||
| Liabilities And Stockholders Equity | 151 | 157 | 162 | 5 | 8 | 13 | 7 | 4 | 5 | 7 | 5 | 10 | ||||||
| Stockholders Equity Note Stock Split Conversion Ratio1 | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | 290 | ||||||
| Common Stock Shares Issued | 1 | 1 | 1 | 1 | 1 | 23 | 0 | 17 | 7 | 6 | 0 | 11 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 1 | 1 | 23 | 0 | 17 | 7 | 6 | 0 | 11 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTranscode Therapeutics, Inc. (RNAZ) — SEC Financial Statements & Analysis
Transcode Therapeutics, Inc. (RNAZ) is a pharmaceutical preparations company, incorporated in DE. Transcode Therapeutics, Inc. trades on Nasdaq as: RNAZ. Transcode Therapeutics, Inc. (RNAZ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Transcode Therapeutics, Inc. carries a market cap of $5.94M, a P/E ratio of -0.14x, a P/B ratio of -0.21x, an enterprise value of $-1.79M, and an EV/EBITDA multiple of 0.04x. On profitability, it posts a Return on Equity (ROE) of 397.59%, a Return on Assets (ROA) of -53.79%, and a Return on Invested Capital (ROIC) of -2233.34%. Per share, it reports EPS of $-44.75, diluted EPS of $-44.75, free cash flow per share of $-23.62, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 74.13% year-over-year and EPS growth of 51.66% year-over-year. On the balance sheet, it maintains a current ratio of 1.97x, a quick ratio of 1.55x, working capital of $5.24M, a debt-to-equity ratio of -0.46x, a debt ratio of 0.08, an interest coverage ratio of -6941.29x, free cash flow of $-22.61M (TTM), and net debt of $-7.73M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.94M
- P/E TTM
- -0.14x
- EPS TTM
- $-44.75
- P/B TTM
- -0.21x
- ROE TTM
- 397.59%
- ROA TTM
- -53.79%
- Debt To Equity
- -0.46x
- Free Cash Flow TTM
- $-22.61M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Transcode Therapeutics, Inc. in?
Transcode Therapeutics, Inc. (RNAZ) operates in the Pharmaceutical Preparations industry.
What exchange does RNAZ trade on?
Transcode Therapeutics, Inc. (RNAZ) trades on the Nasdaq.
Where is Transcode Therapeutics, Inc. incorporated?
Transcode Therapeutics, Inc. is incorporated in DE.
When was Transcode Therapeutics, Inc. (RNAZ)'s most recent SEC filing?
Transcode Therapeutics, Inc. (RNAZ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is RNAZ's market cap?
Transcode Therapeutics, Inc. (RNAZ) has a market capitalization of $5.94M as of 2026-06-30.
What is RNAZ's EPS (earnings per share)?
Transcode Therapeutics, Inc. (RNAZ)'s trailing twelve month EPS is $-44.75 as of 2026-06-30.
What is RNAZ's ROE (return on equity)?
Transcode Therapeutics, Inc. (RNAZ)'s trailing twelve month Return on Equity (ROE) is 397.59% as of 2026-06-30.
What is RNAZ's ROA (return on assets)?
Transcode Therapeutics, Inc. (RNAZ)'s trailing twelve month Return on Assets (ROA) is -53.79% as of 2026-06-30.
What is RNAZ's ROIC (return on invested capital)?
Transcode Therapeutics, Inc. (RNAZ)'s trailing twelve month Return on Invested Capital (ROIC) is -2233.34% as of 2025-12-31.
What is RNAZ's EV/EBITDA?
Transcode Therapeutics, Inc. (RNAZ)'s trailing twelve month EV/EBITDA is 0.04x as of 2026-06-30.